RETRACTED: Randomized Clinical Trial to Assess the Efficacy of Radiotherapy in Primary Mediastinal Large B-Lymphoma

Avilés, Agustín; Neri, Natividad; Fernández, Raúl Ambriz; Huerta‐Guzmán, Judith; Nambo, M. Jesús

doi:10.1016/j.ijrobp.2011.09.012

Cited by 9 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The optimal therapy for PBML has still not been proposed. Autologous hematopoietic stem cell transplantation or multi-agent chemotherapy with rituximab plus CHOP regimen followed by involved field radiotherapy are typically the chosen treatment options (17,(26)(27)(28)(29). However, the exact roles and effects of these treatments are unclear due to the extremely low incidence of the disease.…”

Section: Discussionmentioning

confidence: 99%

Fever and arthralgia as the initial symptoms of primary bone marrow diffuse large B-cell lymphoma: A case report

et al. 2016

View full text Add to dashboard Cite

Primary bone marrow diffuse large B-cell lymphoma (DLBCL) is rare, and only a few cases have been reported. Fever and arthralgia as the initial symptom are extremely rare; however, awareness must be made of this presentation. The current study describes the clinical and pathological findings of a 41-year-old man affected by fever and arthralgia. Blood tests revealed leukopenia and anemia. Multiple bone marrow biopsies were conducted and confirmed the diagnosis of primary bone marrow DLBCL. Primary bone marrow DLBCL is a rare and frequently misdiagnosed subset of non-Hodgkin's lymphoma. The current case demonstrates that utility of bone marrow biopsy for diagnosis should not be ignored, and that repeated bone marrow punctures in multiple locations may be necessary.

show abstract

Section: Discussionmentioning

confidence: 99%

Fever and arthralgia as the initial symptoms of primary bone marrow diffuse large B-cell lymphoma: A case report

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Multiagent chemotherapy with R-CHOP followed by involved field radiotherapy is usually the treatment of choice. [121314] HDCT and autologous bone marrow transplantation as consolidation has been tried in first remission in view of young age of patients and relative absence of marrow involvement. A residual mediastinal mass is often found at the end of therapy owing to the predominant fibrotic component.…”

Section: Discussionmentioning

confidence: 99%

Primary mediastinal large B-cell lymphoma: Clinical features, prognostic factors and survival with RCHOP in Arab patients in the PET scan era

2014

View full text Add to dashboard Cite

Objective:PMBCL is a distinct type of nonhodgkins lymphoma with specific clinicopathological features. To clarify clinical features, treatment alternatives and outcomes, we evaluated 28 Arab patients treated with chemotherapy or radiotherapy between 2006 and 2011.Patients and Methods:PMBCL lymphoma patients identified according to WHO classification and treated at KCCC between 2006 and 2011 were included in this study. Demographic and clinical data are presented as means or medians. Overall survival was estimated using the Kaplan-Meier method. Survival rates were compared using the log-rank test. A P < 0.05 was considered significant.Results:The median age of the patients was 31 years and the male to female ratio was 2:1. Majority of the patients (75%) presented with stage I/II disease. Most had features of local extension like pleural effusion (18%) and SVCO (39%). Only 11% of the patients had bone marrow involvement at presentation. 96% of the patients required biopsy from the mediastinal mass either by image guided core biopsy (75%) or by surgical biopsy. Most patients were treated by RCHOP and involved field radiotherapy. Patients with positive PET scan after RCHOP chemotherapy received salvage chemotherapy and BEAM autologous marrow transplant. The five year OS for the entire group was 85% while the PFS was 73%. Patients who had PET scan for response evaluation had better OS [P = 0.013] and PFS [P = 0.039] when compared with those patients who received only radiotherapy based on CT scan evaluation.Conclusion:PMBCL is a specific lymphoma entity seen in the young with good survival. The role of PET scan for response evaluation and the type of consolidation therapy needs to be further clarified

show abstract

“…For the most part, PMBL is approached therapeutically in a similar way to other subtypes of DLCBL, but with regimens such as R-CHOP followed by involved field radiation there is a high rate of treatment failure and the results are suboptimal [Abramson et al 2011;Aviles et al 2012;Savage et al 2006]. In addition, the long-term consequences of mediastinal radiation in this [Rosenwald et al 2003].…”

Section: Targeting Pmblmentioning

confidence: 99%

Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma

Dunleavy

Grant

Wilson

2012

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

While diffuse large B-cell lymphoma (DLBCL) was once considered to be a single disease entity, recent biological insights have demonstrated that it can be divided up into at least three molecular subtypes. Gene expression profiling has revealed that DLBCL consists of a germinal center B-cell like subtype (GCB), an activated B-cell like subtype (ABC) and a primary mediastinal B-cell lymphoma subtype (PMBL). These three entities arise from different stages of B-cell differentiation and are characterized by distinct mechanisms of oncogenic activation. In GCB DLBCL, the BCL6 transcription factor may play an important role in tumor survival and treatment resistance and strategies that target this are under investigation. ABC DLBCL is characterized by high expression of target genes of the nuclear factor kappa B (NF-κB)/Rel family of transcription factors and strategies that target NF-κB are in clinical trials. PMBL is a distinct clinicopathologic entity that shares many molecular features with nodular sclerosis Hodgkin lymphoma (HL) and may benefit from dose intensity approaches and inhibition of the Janus kinases. Other biologic predictive factors such as MYC and BCL2 may be overexpressed in both the GCB and ABC subtypes and strategies that target these complexes are also being tested.

show abstract

RETRACTED: Randomized Clinical Trial to Assess the Efficacy of Radiotherapy in Primary Mediastinal Large B-Lymphoma

Cited by 9 publications

References 18 publications

Fever and arthralgia as the initial symptoms of primary bone marrow diffuse large B-cell lymphoma: A case report

Fever and arthralgia as the initial symptoms of primary bone marrow diffuse large B-cell lymphoma: A case report

Primary mediastinal large B-cell lymphoma: Clinical features, prognostic factors and survival with RCHOP in Arab patients in the PET scan era

Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma

Contact Info

Product

Resources

About